C Tsompos1, C Panoulis2, K Toutouzas3, A Triantafyllou4, G Zografos3, A Papalois5. 1. Department of Obstetrics & Gynecology, Mesologi County Hospital, Etoloakarnania, Greece. 2. Department of Obstetrics & Gynecology, Aretaieion Hospital, Athens University, Attiki, Greece. 3. Department of Surgery, Ippokrateion General Hospital, Athens University, Attiki, Greece. 4. Department of Biologic Chemistry, Athens University, Attiki, Greece. 5. Experimental Research Centre ELPEN Pharmaceuticals, S.A. Inc., Co., Pikermi, Attiki, Greece.
Abstract
BACKGROUND: This experimental study examined the effect of the antioxidant drug "U-74389G", on a rat model and particularly in a hypoxia - reoxygenation protocol. The effects of that molecule were studied hematologically using blood mean platelets volume (MPV) levels. METHODS: 40 rats of mean weight 231.875 g were used in the study. MPV levels were measured at 60 min of reoxygenation (groups A and C) and at 120 min of reoxygenation (groups B and D). The drug U-74389G was administered only in groups C and D. RESULTS: U-74389G administration kept significantly increased the predicted MPV levels by 12.77 ± 3.07% (p = 0.0001). Reoxygenation time non-significantly decreased the predicted MPV levels by 2.55 ± 3.71% (p = 0.4103). However, U-74389G administration and reoxygenation time together kept significantly increased the predicted MPV levels by 7.09 ± 1.91% (p = 0.0005). CONCLUSIONS: U-74389G administration whether it interacted or not with reoxygenation time kept significantly increased the predicted MPV levels. This finding has great clinical interest in blood clotting and coagulation pathophysiology. Copyright 2016 PBJ-Associação Porto Biomedical/Porto Biomedical Society.
BACKGROUND: This experimental study examined the effect of the antioxidant drug "U-74389G", on a rat model and particularly in a hypoxia - reoxygenation protocol. The effects of that molecule were studied hematologically using blood mean platelets volume (MPV) levels. METHODS: 40 rats of mean weight 231.875 g were used in the study. MPV levels were measured at 60 min of reoxygenation (groups A and C) and at 120 min of reoxygenation (groups B and D). The drug U-74389G was administered only in groups C and D. RESULTS: U-74389G administration kept significantly increased the predicted MPV levels by 12.77 ± 3.07% (p = 0.0001). Reoxygenation time non-significantly decreased the predicted MPV levels by 2.55 ± 3.71% (p = 0.4103). However, U-74389G administration and reoxygenation time together kept significantly increased the predicted MPV levels by 7.09 ± 1.91% (p = 0.0005). CONCLUSIONS: U-74389G administration whether it interacted or not with reoxygenation time kept significantly increased the predicted MPV levels. This finding has great clinical interest in blood clotting and coagulation pathophysiology. Copyright 2016 PBJ-Associação Porto Biomedical/Porto Biomedical Society.
Entities:
Keywords:
Hypoxia; Mean platelets volume; Reoxygenation; U-74389G
Authors: E F Mammen; M H Koets; B C Washington; L W Wolk; J M Brown; M Burdick; N R Selik; R F Wilson Journal: Semin Thromb Hemost Date: 1985-07 Impact factor: 4.180
Authors: Murat Yuce; Musa Cakici; Vedat Davutoglu; Orhan Ozer; Ibrahim Sari; Suleyman Ercan; Murat Sucu; Adnan Dogan; Fethi Yavuz Journal: Blood Coagul Fibrinolysis Date: 2010-12 Impact factor: 1.276